RSSDI Yearbook of Diabetes 2020 Sujoy Ghosh, Sayantan Ray
INDEX
A
Addison's disease 81
Adrenalitis 75
Advanced microvascular disease, development of 27
Alpha-fetoprotein 175
Ambulatory glucose profile 162
American Diabetes Association 33, 81, 128, 164
Anemia 124
Angiotensin-converting enzyme inhibitor 173
Angiotensin-receptor-neprilysin inhibitor 173
Anti-glutamic acid decarboxylase antibody 25, 80
Antihyperglycemic medications, use of 33
Anti-islet cell antibody 80
Antiretroviral therapy 98
Anti-thyroid peroxidase 81
Arginine vasopressin secretion 10
Aspartate aminotransferase 52
Association of Maternal Lactation with Diabetes and Hypertension 15
Atherosclerosis 2, 3
Atherosclerotic cardiovascular disease 139, 145
Atrial fibrillation 144, 145
Autoantibody
loss 18
profile of 80
reversion 18
Autoimmune
diseases 22, 23
disorders 23
thyroid disease 80
Autonomic function, parasympathetic 64
B
Beta-cell function 151
Beta-thalassemia major 1
Blood
glucose 131
fasting 56, 110
self-monitoring of 8587, 89, 149, 162, 165, 172
pressure 59
systolic 22, 168
Body mass index 6, 16, 17, 23, 29, 33, 35, 36, 59, 65, 148
Bone
formation rate 68
histomorphometry 68, 69
mineral density 17, 68, 71
Branched chain amino acids 4
Breastfeeding 16
Brown adipose tissue 4
Bullous pemphigoid 60, 61
risk of 60
C
Canagliflozin 33, 153
Cardiac autonomic
dysfunction 64
neuropathy 64
Cardiovascular death 105
Cardiovascular disease 15, 30, 31, 33, 41, 48, 49, 65, 138, 139, 146
Cardiovascular disorders 134
Cardiovascular outcome trial 138
Carotid intima-media thickness test 53, 54
Charcot's foot 64, 65, 70
Charcot's neuroarthropathy 64, 65, 70
Closed-loop systems 176
Continuous glucose monitoring 53, 54, 8486, 8890, 99, 100, 114, 115, 160163, 165, 171, 172, 176, 177
effect of 84, 160
Continuous subcutaneous insulin infusion 89, 91
Coronary artery disease 44, 45, 146
Coronavirus 37
disease (COVID) 2019 38
C-reactive protein 78
D
Dapagliflozin 106, 122, 142
effect of 105
Deoxyribonucleic acid 11
Depression 66, 67
Diabetes 4, 29, 44, 56, 57
action to control cardiovascular risk in 40, 41, 51
advanced technologies and treatments for 85, 162
complications 66
control and complications trial 86, 162
digital app technology 163
distress scale 150
mellitus 1, 30, 32, 37, 38, 45, 49, 54, 56, 62, 68, 111, 148, 168, 172
gestational 9598, 121, 162, 163, 174, 175
prevalence of 37
type 1 5, 6, 12, 13, 18, 23, 25, 27, 34, 50, 58, 75, 77, 78, 80, 82, 84, 86, 8890, 99, 101, 116, 127, 129, 128, 136, 148, 149, 160, 162, 163, 165, 176
type 2 2, 3, 5, 6, 8, 9, 12, 13, 16, 17, 21, 25, 30, 31, 3336, 38, 39, 42, 4751, 54, 58, 62, 64, 68, 76, 82, 101, 102, 109, 111, 113, 114, 119, 120, 122124, 127132, 134, 135, 138, 139, 141, 142, 145, 146, 148150, 152, 153, 160, 162, 165167, 170, 172, 173, 175
screening 168
Dipeptidyl peptidase-4
enzyme 173
inhibitor 60, 109, 111
protein 61
Dual-energy X-ray absorptiometry 17
E
Empagliflozin 33, 131
effect of 146
efficacy of 144
Enzyme-linked immunosorbent assay 14
Estimated glomerular filtration rate 19, 21, 27, 50, 82, 140, 146, 168
European Association for Study of Diabetes 163, 164
Euthymia 151
Extracellular matrix 167
F
Fatty liver disease, nonalcoholic 2, 3, 52
Foot ulcers, diabetes-associated 118
Fractional flow reserve 44
G
Genome-wide
analysis 12
association studies 5, 6, 9
Glomerular filtration rate 50, 77, 78
Glucagon
like peptide 6, 12, 33, 107, 114, 115, 132, 134, 173
receptor 111
antagonist 111
Glucokinase 25
Glucose
homeostasis, abnormal 1
tolerance, normal 170, 171
Glutamic acid decarboxylase 24, 25
Glycemia 113, 114
pancreatic beta-cell function across spectrum of 170
reduction approaches 113
Glycemic control 56, 84, 86, 148, 160
Glycemic index 7
H
Heart failure 105, 106, 122, 139, 140, 144, 145, 146
Hemoglobin, glycated 54, 59, 84, 148, 160, 163, 172
Hepatitis
B virus 62
C virus 62
chronic viral 62, 63
Hepatocyte nuclear factor 25
High-density lipoprotein cholesterol 22
Highly active antiretroviral therapy 98
Homeostasis model assessment 1, 122, 170
Human chorionic gonadotropin 175
Human leukocyte antigen 81
Hyperbaric oxygen therapy 118
Hyperglucagonemia 10
paradoxical 11
Hyperglycemia 57, 160
Hyperinsulinemia 10
Hypoglycemia 86, 90, 116, 127, 160
severe 126
Hypophysitis 75
I
Immune checkpoint inhibitor 75, 76
Impaired glucose tolerance 1, 170
Indian Demographic Health Survey 29
Indian diabetes risk score 42
Insulin 33
antibody 18
autoantibody 24, 25, 80
resistance 13
secretion 59
Insulinogenic index 171
Intermittently-scanned glucose monitoring 161
International Diabetes Management Practices Study 148
Intrauterine growth restriction 31
Islet amyloid polypeptide 174
Islet autoantibodies 18
absence of 24
Islet cell
antibody 18
autoantibody 80
J
Juvenile Diabetes Research Foundation 87
K
Ketoacidosis, diabetic 77
Kidney disease 138, 139
chronic 19, 20, 46, 47, 50, 82, 119, 139, 167, 170
diabetic 21, 47, 50, 77, 78
nonalbuminuric chronic 49
L
Left ventricular mass index 146
Linagliptin 138, 139
Liquid chromatography-mass spectrometry 168
Liraglutide 33
Liver
biopsy 53
fatty acid-binding protein 83
iron concentration 1
transplantation 31, 32
Low-density lipoprotein 59, 168
Lower glycemic index 7
Lower high-density lipoprotein 24
M
Madras Diabetes Research Foundation 42, 43
Magnetic resonance imaging 1
Major adverse cardiovascular events 44, 45, 51, 126, 167, 168
Major histocompatibility complex 6
Maturity onset diabetes of young 24, 25
Mealtime insulin 137
Meglitinides 33
Menarche, delayed 27
Metabolic syndrome 32
Metformin 95, 109, 124, 131, 153
monotherapy 111
Microbiota, effect of 121
Microtubule actin cross-linking factor 1 8
Microvascular diseases 48
Mixed meal test 114, 115
Multiple daily insulin injections 166
Multiple subcutaneous injections 100
Multiple-dose injection therapy 86
Mycobacterium avium 14
Myocardial infarction 44
N
National Health and Nutrition Examination Survey 27, 33, 42, 43, 48, 49
Neonatal intensive care unit 95, 100
Nephropathy, diabetic 78
Nervous system
parasympathetic 64, 65
sympathetic 64, 65
Neutrophil gelatinase-associated lipocalin 83
New York Heart Association 105, 122, 123
New-onset diabetes after transplantation 32
O
Obesity 114
prevalence of 95
Oral antidiabetic drugs 131, 134, 135, 152
Oral disease 48
Oral glucose
lowering drugs 148, 149
tolerance test 56, 169, 171, 175
Oral semaglutide 119, 131
Osteopenia 16
Osteoporosis 16
Oxyntomodulin 114, 115
P
Pancreatic alpha-cells 111
Pancreatic islet autoantibodies 13
Pancreatic polypeptide 56
Pancreatitis, chronic 56
Paratuberculosis 14
Peptide innovation 120
Placental growth factor 102
Plasma glucose, fasting 111, 121, 141
Postprandial plasma glucose 141
Post-transplant metabolic syndrome 31, 32
Pre-eclampsia 102
Primary polydipsia analysis 142
Psychologic insulin resistance 150
Q
Quality-adjusted life years 49
Quantitative insulin sensitivity check index 1
R
Randomized controlled trials 79, 85, 87, 88, 107, 121, 124, 131, 135, 160
Randomized double-blind placebo-controled study 70
Rapid acting insulin analogs 130
Real-time continuous glucose monitoring 86, 87, 99
Recombinant human parathyroid hormone 70
Remogliflozin etabonate 141, 142
Renal disease
end-stage 46, 47, 50, 78, 82
progression of 82
Renal insufficiency, chronic 50
Renin-angiotensin-aldosterone system 78
Retinol-binding protein 4 170, 171
Retinopathy 58
Revised National Tuberculosis Control Program 29
Roux-en-Y gastric bypass 115
S
Semaglutide 132, 133, 153
Sensor-augmented pump 91
Sensor-integrated pump therapy, use of 90
Serum angiogenic markers 101
Serum placental growth factor 101
Single nucleotide polymorphism 6
Sodium-glucose cotransporter-2 34, 122, 123, 132, 142, 143, 170
inhibitor 105, 107, 141, 144147
Steatohepatitis, nonalcoholic 52, 112
Stumvoll indexes 171
Suboptimal glycemic control 148
Sulfonylureas 33, 109
T
Technosphere insulin 116
Teriparatide 70
Thiazolidinediones 33
Thyroiditis 75
Triglycerides 22
Tuberculosis 28, 29
U
Ultrasonography 37, 63
Upper gastrointestinal endoscopy 63
Uric acid 78
Urinary albumin excretion 78
Urine albumin-to-creatinine ratio 22
V
Vascular diseases 48
Vascular endothelial growth factor 102
Very low-calorie diet 114, 115
Vitamin
B12 124
deficiency 124
D 95, 96
supplementation 38
W
World Health Organization 17, 36
Z
Zinc transporter 13, 24, 80
×
Chapter Notes

Save Clear